VADUZ – November 12, 2026 -- Implantica AG will publish its Q3 2026 interim report at 8:00 a.m. CET on November 19, one week after announcing the date on November 12. The company will present the results to investors at 15:00 CET the same day, which gives the market seven hours to read the report before management speaks.
The presentation will be held in English by webcast, with a separate teleconference. Webcast access is open by link. Teleconference participants must register first and will then receive a dial-in number and a conference ID.
Three executives will present the Q3 2026 results
CEO Peter Forsell, the CFO and Chief Corporate Affairs Officer Nicole Pehrsson are the announced speakers. Pehrsson is also the investor relations contact named in the release.
Implantica's shares trade on the Nasdaq First North Premier Growth Market in Stockholm under the ticker IMP A SDB. FNCA Sweden AB is the company's Certified Adviser.
RefluxStop remains the lead product under review
Implantica describes RefluxStop, an implant for gastroesophageal reflux disease (GERD), as its lead product. The company says the device is FDA approved and CE-marked. It also says five-year clinical outcomes have appeared in peer-reviewed journals.
The release gives no preview of Q3 2026 figures and no comparison with earlier quarters.